Pfizer
PFE
About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Employees: 81,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.79% more ownership
Funds ownership: 64.45% [Q1] → 65.24% (+0.79%) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 1,156 | Existing positions reduced: 1,208
5% less funds holding
Funds holding: 2,889 [Q1] → 2,756 (-133) [Q2]
5% less capital invested
Capital invested by funds: $94.8B [Q1] → $90B (-$4.85B) [Q2]
22% less call options, than puts
Call options by funds: $2.59B | Put options by funds: $3.32B
35% less funds holding in top 10
Funds holding in top 10: 43 [Q1] → 28 (-15) [Q2]
37% less first-time investments, than exits
New positions opened: 142 | Existing positions closed: 226
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Citigroup
Andrew Baum
|
$26
|
Neutral
Maintained
|
6 Aug 2025 |
|
Morgan Stanley
Terence Flynn
|
$33
|
Equal-Weight
Maintained
|
6 Aug 2025 |
|
B of A Securities
Tim Anderson
|
$28
|
Neutral
Maintained
|
6 Aug 2025 |
Financial journalist opinion
Based on 71 articles about PFE published over the past 30 days
